Compensated advanced chronic liver disease (cALD) refers to a spectrum of advanced liver fibrosis and cirrhosis in asymptomatic patients. Elastography, which measure liver stiffness has been recommended as non-invasive diagnostic method.

  • What are the limitations when using liver stiffness measurements for diagnosis?
  • What role can blood-based serum markers play?
  • Should the measurement cut offs be reviewed for different patient populations?

This EASL studio is supported by Boehringer Ingelheim and Siemens Healthineers. EASL has received no input from Boehringer Ingelheim and Siemens Healthineers with regards to the content of this programme.

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Related episode:

S2E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?






Thomas Reiberger is a hepatologist at the Medical University of Vienna focusing on translational research in the field of advanced chronic liver disease. His Christian-Doppler Laboratory for Portal Hypertension and Liver Fibrosis deciphers molecular mechanisms involved in fibrogenesis and fibrosis regression and evaluates novel treatment options for portal hypertension and antifibrotic therapies in preclinical studies. As a physician, he heads the liver outpatient clinic, the Ultrasound/Elastography unit and the post liver transplant care at the Medical University of Vienna. Currently, he also serves as the Scientific Secretary of the Baveno Cooperation.


Maja Thiele Maja Thiele is Professor of Hepatology at Department of Gastroenterology and Hepatology, Odense University Hospital and University of Southern Denmark. She works to reduce morbidity and mortality from alcohol-related liver disease, for the benefit of an otherwise stigmatized patient group. Her research focuses on the development and validation of diagnostic and prognostic biomarkers, with a particular focus on early disease detection and cost-effective referral pathways. Maja Thiele was an elastography expert contributor to EASL Clinical Practice Guidance, the BAVENO VII consensus statement, and AASLD clinical guidance. She has also been a partner in the European research consortia GALAXY, LiverScreen, MicrobPredict and SALVE.
Manolis Tsochatzis

Emmanuel Tsochatzis is a Professor of Hepatology and Consultant Hepatologist at the UCL Institute for Liver and Digestive Health in the Royal Free Hospital, London, UK and Head of the Centre for Metabolic Liver Diseases. His clinical and research interests include NAFLD, cirrhosis and portal hypertension and non-invasive fibrosis assessment. He is a member of the EASL scientific committee and Governing Board since 2019. He has led several international research collaborations resulting in more than 260 publications in peer reviewed journals. He has received funding for his research from NIHR, EASL and EU Horizon 2020.